Advaxis Inc.

0.4690-0.0502-9.67%Vol 9.01M1Y Perf -24.52%
Apr 16th, 2021 16:00 DELAYED
BID0.4620 ASK0.4680
Open0.4941 Previous Close0.5192
Pre-Market- After-Market0.48
 - -  0.01 2.35%
Target Price
4.30 
Analyst Rating
— 0.00
Potential %
816.84 
Finscreener Ranking
★★★★     54.06
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     48.01
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     43.93
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap56.46M 
Earnings Rating
Buy
Price Range Ratio 52W %
15.70 
Earnings Date
10th Jun 2021

Today's Price Range

0.46200.5000

52W Range

0.26391.57

5 Year PE Ratio Range

-3.1074.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-29.59%
1 Month
-46.21%
3 Months
-23.11%
6 Months
15.63%
1 Year
-24.52%
3 Years
-98.16%
5 Years
-99.68%
10 Years
-99.84%

TickerPriceChg.Chg.%
ADXS0.4690-0.0502-9.67
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
9.30
9.90
0.11
0.15
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-1 207.80
-1 104.30
-2 867.20
-83.61
RevenueValueIndustryS&P 500US Markets
1.87M
0.02
-58.23
1.26
Earnings HistoryEstimateReportedSurprise %
Q04 2020--0.08-
Q03 2020--0.09-
Q02 2020--0.10-
Q01 2020--0.15-
Q04 2019--0.15-
Q03 2019-1.24-1.0019.35
Q02 2019-1.19-1.32-10.92
Q01 2019-4.202.25153.57
Earnings Per EndEstimateRevision %Trend
10/2019 QR-1.370.00-
10/2019 FY-2.700.00-
1/2020 QR-0.630.00-
10/2020 FY-2.410.00-
Next Report Date10th Jun 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume9.01M
Shares Outstanding120.38M
Trades Count12.89K
Dollar Volume8.02M
Avg. Volume12.06M
Avg. Weekly Volume6.78M
Avg. Monthly Volume4.01M
Avg. Quarterly Volume10.78M

Advaxis Inc. (NASDAQ: ADXS) stock closed at 0.469 per share at the end of the most recent trading day (a -9.67% change compared to the prior day closing price) with a volume of 9.09M shares and market capitalization of 56.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Advaxis Inc. CEO is Kenneth A. Berlin.

The one-year performance of Advaxis Inc. stock is -24.52%, while year-to-date (YTD) performance is 34%. ADXS stock has a five-year performance of -99.68%. Its 52-week range is between 0.2639 and 1.57, which gives ADXS stock a 52-week price range ratio of 15.70%

Advaxis Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 2.24, a price-to-sale (PS) ratio of 37.86, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.24%, a ROC of -49.40% and a ROE of -54.41%. The company’s profit margin is -83.61%, its EBITDA margin is -1 104.30%, and its revenue ttm is $1.87 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Advaxis Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Advaxis Inc.’s next earnings report date is 10th Jun 2021.

The consensus rating of Wall Street analysts for Advaxis Inc. is (0), with a target price of $4.3, which is +816.84% compared to the current price. The earnings rating for Advaxis Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Advaxis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Advaxis Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 32.01, ATR14 : 0.11, CCI20 : -194.13, Chaikin Money Flow : -0.42, MACD : -0.09, Money Flow Index : 8.85, ROC : -35.38, RSI : 39.97, STOCH (14,3) : 2.09, STOCH RSI : 0.05, UO : 22.92, Williams %R : -97.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Advaxis Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Advaxis Inc.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

CEO: Kenneth A. Berlin

Telephone: +1 609 452-9813

Address: 305 College Road East, Princeton 8540, NJ, US

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

Bearish Bullish

53%47%

News

Stocktwits